Camblong Jurgi sold $66K of SOPH
Camblong Jurgi (Executive Chairman) sold 8,500 shares of SOPHiA GENETICS SA (SOPH) at $7.76 on 2026-11-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, providing new data for traders.
Market read
A modest insider sale may cause short‑term price pressure but is unlikely to move the stock significantly.
What to watch
The insider retains a large stake (over 3 million shares), indicating continued confidence.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
Executive Chairman sold 8,500 shares for $65,948 via a 10b5‑1 plan, reducing his stake.
likely slight pressure as the market prices in the insider sell
A 10b5‑1 sale by a top executive, though modest in dollar terms, can be interpreted as a lack of confidence and may trigger short‑term selling.
Market effects
Minimal impact on the broader biotech/genomics sector.
Limited to investors tracking SOPHiA GENETICS.
Low global relevance.
Counterpoint
The sale could be routine portfolio rebalancing, not a negative signal.
Key entities
- PersonCamblong Jurgi
Executive Chairman of SOPHiA GENETICS SA
- CompanySOPHiA GENETICS SA
Swiss genomics and AI-driven diagnostics firm listed on NASDAQ as SOPH



